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Abstract: 
Background: Even though intra-abdominal candidiasis (IAC) has been increasingly recognized, with associated 
high morbidity and mortality rates, its pathogenesis remains poorly understood. This model aims to study the 
pathogenicity and invivo susceptibility of non-albicans Candida species associated with IAC in human in order to 
predict the frequency of infections, outcome of clinical disease and response to antifungal therapy.  
Methodology: Both immunosuppressed and immunocompetent female CD-1 mice were challenged 
intraperitoneally with 5 x 108 CFU/ml inoculum of five non-albicans Candida strains; Candida glabrata, Candida 
parapsilosis, Candida lipolytica, Candida tropicalis and Candida guilliermondii. Mice were closely observed for 
symptoms. Treated groups received voriconazole (40 mg/kg/day) or micafungin (10 mg/kg/day) 24 hours after 
infection depending on invitro susceptibility results. Survival rate, mean survival time and fungal tissue burdens 
were recorded for all groups.  
Results: All infected groups developed hepatosplenomegaly, peritonitis and multiple abscesses on intra-abdominal 
organs and mesenteries. C. glabrata and C. lipolytica represented the most and the least virulent strains 
respectively in terms of survival rate, mean survival time and fungal burden in both immunosuppressed and 
immunocompetent models. Following treatment, all immunocompetent animals survived the entire duration of 
experiments (0% mortality rate), while mortality rate was relatively high (20-60%) in immunosuppressed mice. 
Treatment failed to eradicate the infection in immunosuppressed mice despite significant decrease of the fungal 
burden and increase mean survival time.  
Conclusion: This study reports an increasing pathogenicity of non-albicans Candida species, with persistent 
infection among immunosuppressed animals. 
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Abstrait: 
Contexte: Bien que la candidose intra-abdominale (CAI) soit de plus en plus reconnue, avec des taux de morbidité 
et de mortalité élevés associés, sa pathogenèse reste mal comprise. Ce modèle vise à étudier le pouvoir pathogène 
et la susceptibilité in vivo d'espèces de Candida non albicans associées à l'IAC chez l'homme afin de prédire la 
 




fréquence des infections, l'évolution de la maladie clinique et la réponse au traitement antifongique.              
Méthodologie: Des souris femelles CD-1 immunodéprimées et immunocompétentes ont été stimulées par voie 
intrapéritonéale avec un inoculum de 5 x 108 UFC / ml de cinq souches Candida non albicans; Candida glabrata, 
Candida parapsilosis, Candida lipolytica, Candida tropicalis et Candida guilliermondii. Les symptômes ont été 
observés de près chez les souris. Les groupes traités ont reçu du voriconazole (40 mg/kg/jour) ou de la 
micafungine (10 mg/kg /jour) 24 heures après l'infection, en fonction des résultats de sensibilité invitro. Le taux de 
survie, la durée de survie moyenne et la charge en tissu fongique ont été enregistrés pour tous les groupes.                
Résultats: Tous les groupes infectés ont développé une hépatosplénomégalie, une péritonite et de multiples abcès 
aux organes intra-abdominaux et au mésentère. C. glabrata et C. lipolytica représentaient respectivement les 
souches les plus et les moins virulentes en termes de taux de survie, de durée de survie moyenne et de charge 
fongique dans les modèles immunodéprimés et immunocompétents. Après le traitement, tous les animaux 
immunocompétents ont survécu à toute la durée des expériences (taux de mortalité de 0%), tandis que le taux de 
mortalité était relativement élevé (20 à 60%) chez les souris immunodéprimées. Le traitement n'a pas réussi à 
éradiquer l'infection chez les souris immunodéprimées malgré une réduction significative de la charge fongique et 
une augmentation du temps de survie moyen.                 
Conclusion: cette étude rapporte une pathogénicité croissante des espèces de Candida non albicans, avec une 
infection persistante chez les animaux immunodéprimés. 
Mots-clés: intra-abdominal, candidose, non albicans, invivo, souris. 
 
Introduction: 
Candida species are important fungal 
pathogens that can survive in different 
anatomical sites (1, 2). Invasive candidiasis is 
the most frequently encountered fungal 
disease among hospitalized patients. This 
includes candidaemia and intra-abdominal 
candidiasis (IAC), which manifests as peri- 
tonitis and intra-abdominal abscesses (3, 4). 
Despite the high frequency of IAC among 
critically ill patients, it remains understudied 
compared to candidemia (5-7). Over the last 
decades a progressive increase in the 
epidemiology of non-albicans Candida 
infections has been recorded (8-11). The 
expanding population of patients with severe 
illnesses or immunosuppression, abdominal 
surgeries, use of broad-spectrum antibiotics, 
intravenous catheters and parentheral nutrition 
are factors contributing to the changing 
epidemiology of these infections (11, 12). 
 The shift toward non-albicans Candida 
pathogens is accompanied with the emergence 
of resistance against commonly used 
antifungal agents rendering the treatment 
challenging especially in critically ill individuals 
(9-11, 13). IAC has been associated with poor 
outcomes in some patients (11, 14). Lack of 
adequate therapy and source control and 
severity of illness are the most important 
determinants of poor outcome (12). Research 
on IAC has several limitations including 
diagnosis difficulties due to the clinical 
heterogeneity of the disease (7, 14, 15). 
Moreover, treatment of this type of infection is 
challenging because it is usually based on 
previous case reports and experience gained 
from other forms of fungal disease (5). In 
addition, the emergence of strains resistant to 
the available antifungals has further comp- 
licated the treatment of IAC (16).  
 Animal models simulating IAC will 
provide a useful tool for understanding of 
disease pathogenicity, host response and 
evaluation of the therapeutic strategies in the 
absence of clinical trials (14,17). Since most 
animal models of candidiasis have been used 
for disseminated infections through intra- 
venous route (3), the present study aims to 
provide a model simulating IAC caused by non-
albicans Candida species in both immuno- 
competent and immunosuppressed mice via 
intraperitoneal introduction of pathogen and 
for invivo study of the pathogenicity and 
evaluation of treatment outcomes.  
Material and Methods: 
Test strains     
 Five non-albicans Candida strains were 
selected among isolates obtained from patients 
previously diagnosed with IAC at Ain Shams 
University Specialized Hospital (ASUSH), Cairo, 
Egypt. Isolates were identified using Matrix-
Assisted Laser Desorption Ionization-Time of 
Flight Mass Spectrometry analysis (MALDI-TOF 
MS) (VITEK® MS, bioMérieux Inc., Marcy l' 
Etoile, France). The invitro susceptibility of the 
strains to fluconazole, voriconazole, caspo- 
fungin, micafungin, amphotericin B and flu- 
cytosine was determined using the Vitek2 
system (bioMérieux Inc., Marcy l' Etoile, 
France). (This was part of a surveillance 
 
 





Table 1: non-albicans Candida species used in this study 
Candida species  Clinical origin Type of IAI Patient type AUMC no. 
C. glabrata Peritoneal fluid Secondary peritonitis Liver transplantation 13949 
C. parapsilosis Peritoneal fluid Secondary peritonitis Appendectomy 13952 
C. lipolytica Peritoneal fluid Secondary peritonitis Liver transplantation 13950 
C. tropicalis Peritoneal fluid Secondary peritonitis CAPD 13948 
C. guilliermondii Bile Cholecystitis/cholangitis Liver transplantation 13951 
IAI = Invasive Abdominal Infection; AUMC = Assiut University Mycological Centre; CAPD = Continous Ambulatory Peritoneal Dialysis  
 
study on IAC previously presented as an e-
poster in the 20th Congress of the 
International Society of Human and Animal 
Mycology, ISHAM, Amsterdam, 2018).  
 MALDI-TOF MS and Vitek2 assays were 
performed at The Children’s Cancer Hospital 
Egypt 57357 (CCHE), Cairo, Egypt. All the 
isolates were deposited in the culture collection 
of Assiut University Mycological Centre 
(AUMC), Assiut University, Assiut, Egypt, and 
their numbers and identification are listed in 
Table 1.  
Test animals      
 Pathogen-free female outbred CD-1 
mice aged 4-5 weeks old (22-30 gm) 
purchased from The Nile Company for 
Pharmaceuticals and Chemical Industries, 
Cairo, Egypt; were used for the invivo studies. 
The test animals were maintained in the 
animal facility of The Research and Training 
Centre on Vectors of Diseases, Faculty of 
Science, Ain Shams University, Cairo, Egypt. 
They were housed in a non-stressful 
environment in cages of 5 mice each repres- 
enting a group and left to acclimatize for one 
week before infection, with access to food and 
water ad libitum.  
Inoculum preparation   
 The yeast strains were cultured on 
CandiSelect™ 4 chromogenic media (Bio-Rad, 
Marnes la Coquette, France) to ensure purity, 
and then cultured overnight in yeast extract-
peptone dextrose broth (YPD) (1% yeast 
extract, 2% peptone, 2% D-glucose) with 
shaking at 30C.  Yeast cells were harvested by 
centrifugation, washed twice with phosphate 
buffered saline (PBS) and adjusted to the 
desired concentration of 5 x 108 CFU/ml (3) on 
a haemocytometer using PBS. Dilutions of the 
inocula were plated on SDA plates to ensure 
the correct inoculum was injected. 
Infection assay    
 Each yeast strain was tested on both 
immunosuppressed and immunocompetent 
mice. Mice were immunosuppressed by 
administering cyclophosphamide intraperi- 
toneally at a dose of 200 mg/kg for                                 
3 consecutive days prior to infection. Both 
immunosuppressed and immunocompetent 
mice were then infected intraperitoneally.                
A control group was injected with PBS only. 
Challenged mice were closely observed daily 
for signs of the disease. Infected mice were 
sacrificed following administration of a dose of 
200 mg/kg sodium pentobarbitone intra- 
peritoneally when infected mice show severely 
reduced mobility, inability to reach food or 
water, weight reduction, hunched posture and 
fur ruffling.  
Antifungal therapy    
 For all treatments, therapy began 24 
hours after infection. According to Vitek2 
results for each test strain, treatment was 
initiated with intraperitoneal dosage of 40 
mg/kg of voriconazole (Vfend; VRC, Pfizer Inc., 
Egypt) once daily for 7 consecutive days. 
Micafungin (Mycamine; Astellas Toyama Co., 
Ltd. Japan) was administered intraperitoneally 
with a dose of 10 mg/kg/day for 6 consecutive 
days in a 0.2 ml volume. The doses were 
determined according to previous studies (18, 
19). To prevent bacterial infections, mice 
received 5mg/kg/day ceftazidime subcutan- 
eously.  
Fungal burden and histopathology  
 For tissue burden, mice were sacrificed 
on day 3 post-infection and one day after 
treatment was completed in treated groups. 
The kidney, liver, spleen and pancreas were 
aseptically excised and washed with sterile PBS 
and homogenized in 5 ml sterile PBS on ice. 
The serially diluted homogenates were plated 
 




onto SDA and incubated at 37C. Colonies were 
counted to determine the colony-forming units 
(CFU) per gram tissue. Counts were expressed 
as log10 CFU per gram tissue. To assess the 
presence of peritonitis, the peritoneal cavity 
was washed with PBS, the effluent was 
collected, centrifuged and the pellet was re-
suspended in 600 l sterile water containing 
0.01% bovine serum albumin.  The undiluted 
suspension was plated on SDA plates and the 
CFU was counted (20).   
 For histopathological analysis, the 
liver, kidneys, spleen and pancreas were 
excised and immediately fixed in 10% neutral 
buffered formalin and embedded in paraffin. 5 
m sections were cut and stained with 
haematoxylin and eosin (H&E) for tissue 
morphology and Periodic Acid-Schiff (PAS) 
reagent to visualize fungal elements in tissue. 
Tissue sections were examined using light 
microscope (B-500T, Optika, Italy) and images 
were captured using a 3.1-megapixel eyepiece 
USB camera (C-B3 Optika, Italy) with Scope 
Image 9.0 software. 
Statistical analysis    
 Data were analyzed using IBM SPSS 
Statistics for Windows, Version 25.0 (2017, 
Armonk, NY: IBM Corp.) A one-way analysis of 
variance (ANOVA test) was used when 
comparing more than two means. For multiple 
comparisons between different variables, Post 
Hoc tests: Tukey HSD was done and p<0.05 
was considered significant. 
Results: 
 Five non-albicans Candida species used 
in this study were C. glabrata, C. parapsilosis, 
C. lipolytica, C. tropicalis and C. guilliermondii. 
Survival studies revealed that C. glabrata and 
C. tropicalis caused the highest mortality in 
both immunosuppressed and immuno- 
competent models (Table 2).  
Table 2: Mean survival time (days), survival range (days) and mortality rates (%) among different study groups 
 C. glabrata C. parapsilosis C. lipolytica C. tropicalis  C. guilliermondii 
Immunosuppressed group 
Mean ± SD 7.20±2.17 7.60±1.34 32.6±16.7a 7.80±1.48 9.80±1.92 
Range (5-10) (6-9) (14-45) (6-10) (8-13) 
Mortality %  100  100  40  100  100  
Immunosuppressed-treated group 
Mean ± SD 29.00±14.68 32.60±16.99 40.00±11.18 39.60±12.07 33.00±16.45 
Range (16-45) (13-45) (20-45) (18-45) (14-45) 
Mortality % 60 40 20 20 40 
Immunocompetent group 
Mean ± SD 11.80±1.64b 25.8±17.54 45.00±0.00c 11.40±1.14d 32.00±17.80e 
Range (10-14) (12-45) 45 (10-13) (12-45) 
Mortality % 100  60  0  100  40  
Immunocompetent-treated group 
Mean ± SD 45.00±0.00f  45.00±0.00 45.00±0.00 45.00±0.00g 45.00±0.00 
Range 45 45 45 45 45 
Mortality % 0  0  0  0  0  
a vs other immunosuppressed Candida groups, p0.001. 
b, d vs C. lipolytica and C. guilliermondii immunocompetent infected groups, p<0.05. 
c, e vs C. glabrata and C. guilliermondii immunocompetent infected groups, p<0.001 and p<0.05 respectively. 
f vs C. glabrata immunocompetent infected group, p<0.001. 
g vs C. tropicalis immunocompetent infected group, p<0.001.   
 




 Candida parapsilosis and Candida 
guilliermondii caused 100% mortality rates 
among immunosuppressed mice but a 
relatively lower mortality rates among 
immunocompetent ones (60% and 40% 
respectively). Candida lipolytica caused the 
lowest mortality rates in both immuno- 
suppressed and immunocompetent groups. 
From the study of mean survival time, C. 
lipolytica infected immunosuppressed mice had 
significantly longer survival time (p<0.001) 
while there was no significant difference in the 
mean survival time among other Candida 
species. Among the immunocompetent groups, 
mice infected with C. lipolytica and C. 
guilliermondii had the highest mean survival 
time while those infected with C. glabrata and 
























































Fig. 2: Gross morphology of intra-abdominal organs of mice infected with Candida species. (a) normal control (b) 
multiple liver abscess (arrows) caused by C. glabrata, (c) severe spleen enlargement (arrows) due to C. tropicalis 
infection, (d) liver and mesenteric abscesses (arrows) caused by C. parapsilosis and (h) & (i) abscess formation 
(arrows) by C. guilliermondii and C. lipolytica respectively 
b c a 
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 On gross morphology of organs (Fig. 
2), hepatosplenomegaly was the first notable 
sign in nearly all the infected immuno- 
suppressed mice in all Candida groups. 
Enlarged, mottled, and markedly congested 
liver with multiple abscesses of varying sizes 
were observed especially in C. glabrata. 
However, some immunocompetent mice 
showed macroscopically normal livers even 
though microscopic abnormalities were seen on 
histological examination. Significant splenic 
enlargement was observed in all groups, with 
some mice showing severe congestion of the 
spleen accompanied with abscesses and white 
patches. Kidneys were slightly enlarged with 
white patches in some infected animals and 
color change in others. Few pancreatic 
abscesses were observed only in immuno- 
suppressed animals infected with C. tropicalis. 
Abscesses were also observed on the 
peritoneum and mesenteric membranes.
 Haematoxylin and Eosin (H&E) tissue 
preparations (Fig.3) revealed that kidneys from 
all infected groups exhibited variable 
pathological changes represented in glomerular 
and tubular damage with marked infiltration of 
lymphocytes and interstitial haemorrhage. 
Liver sections also showed disorganized 
hepatic parenchyma with congestion and 
dilation of blood sinusoids and inflammatory 
cells infiltration, and diffuse Kupffer cells was 
observed between sinusoids and around 
congested central veins. Spleen of infected 
mice showed extravasation of RBC's with 
multifocal granulomatous inflammation and 
abundant neutrophilic infiltration. Pancreatic 
tissue preparations from C. tropicalis infected 
immunosuppressed mice revealed scanty 
epithelial cells with mixed acute and chronic 
inflammatory infiltrates (Fig. 4).  
 PAS-stained tissue sections confirmed 
the presence of extensive fungal elements in 
all organs of both immunocompetent and 
immunosuppressed infected groups (Fig. 5).  
      
   
 
Fig. 3: Photomicrograph of the liver and spleen sections from different Candida groups. (a) Control mouse liver 
section, (g) Control spleen section, (b, h) liver and spleen sections from C. glabrata group, (c, i) liver and spleen 
sections from C. parapsilosis group, (d, j) liver and spleen sections from C. lipolytica group, (e, k) liver and spleen 








Fig. 4: photomicrograph of pancreatic tissue preparations, (a) control pancreas mouse section (H&E 400x),                   
(b) pathological changes caused by C. tropicalis (H&E 400x), (c) fungal element s of C. tropicalis (PAS 400x) 
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Fig. 5: Photomicrograph showing fungal elements in liver (a-e) and spleen (f-j) tissue preparations of infected 
mice. (a,f) C. glabrata, (b,g) C. parapsilosis, (c,h) C. lipolytica, (d,i) C. tropicalis, (e,j) C. guilliermondii. (PAS 400x)  
a b c d e 
f g h i j 
Table 3: Fungal tissue burden of infected mice in all groups 
Organ 
Fungal Tissue Burden (Log10CFU/gm) 
C. glabrata C. parapsilosis C. lipolytica C. tropicalis C. guilliermondii 
Immunosuppressed 
Kidney 6.60 ± 0.78a 5.45 ± 0.17  3.86 ± 0.29d 5.21 ± 0.45 5.19 ± 0.30 
Liver 5.80 ± 0.67b 4.94 ± 0.33  3.70 ± 0.47e 4.48 ± 0.19 4.52 ± 0.37 
Spleen 6.48 ± 0.69c 5.22 ± 0.32  3.54 ± 0.27f 5.14 ± 0.30 5.02 ± 0.36 
Pancreas 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 2.09 ± 0.50h  0.00 ± 0.00 
Peritoneal wash 3.77 ± 0.35 3.60 ± 0 .40 2.53 ± 0.3 g 3.83 ± 0.12 3.53 ± 0.05 
Immunosuppressed-treated i 
Kidney 2.19 ± 0.99 1.64 ± 0.32 1.43 ± 0.21 1.69 ± 0.49 1.74 ± 0.37 
Liver 1.92 ± 0.83 1.33 ± 0.29 1.52 ± 0.10 1.43 ± 0.33 1.37 ± 0.31 
Spleen 2.15 ± 1.15 1.38 ± 0.34 1.57 ± 0.36 1.55 ± 0.52 1.88 ± 0.47 
Pancreas 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Peritoneal wash 1.27 ± 0.06 1.22 ± 0.24 1.14 ± 0. 06 1.07 ± 0.05 1.08 ± 0.63 
Immunocompetent 
Kidney 4.97 ± 0.56j 3.69 ± 0.19 2.26 ± 0.10n 3.54 ± 0.35 3.72 ± 0.85 
Liver 4.82 ± 0.15k 3.53 ± 0.17 2.28 ± 0.12 o  3.20 ± 0.19 3.57 ± 0.26 
Spleen 4.67 ± 0.08l 3.63 ± 0.27 2.33 ± 0.07 p  3.65 ± 0.33 3.66 ± 0.10 
Pancreas 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Peritoneal wash 3.86 ± 0.08 m 3.37 ± 0.06 2.16 ± 0.09 q 3.12 ± 0.14 3.41 ± 0.21 
Immunocompetent-treated r 
Kidney 0.09 ± 0.15 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Liver 0.03 ± 0.03 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Spleen 0.03 ± 0.02 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Pancreas 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Peritoneal wash 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
(a-c) vs other immunosuppressed groups; p0.005, p<0.05, p0.001 respectively 
(d-g) vs other immunosuppressed groups; p0.001, p<0.05, p<0.001 respectively 
(h) vs other immunosuppressed groups; p<0.001 
(i) vs immunosuppressed groups; p<0.001  
(j-m) vs other immunocompetent groups; p<0.001 
(n-q) vs other immunocompetent groups; p<0.001  
(r) vs immunocompetent groups; p<0.001 
 
 




 Fungal burden results among 
immunosuppressed mice (Table 3) showed that 
C. glabrata had significantly higher kidney, 
liver and spleen burdens than other Candida 
species (Fig. 6). Candida parapsilosis, C. 
tropicalis and C. guilliermondii had statistically 
similar fungal burden in the kidneys but higher 
C. guilliermondii spleen burdens.  
 All tested Candida species were 
capable of causing peritonitis with no 
significant difference between their peritoneal 
wash burdens. C. lipolytica showed the least 
fungal burden of all organs among immuno- 
suppressed mice. Of note, only C. tropicalis 
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 Comparatively, kidneys, liver and 
spleen, of C. glabrata and C. lipolytica infected 
animals had the highest and lowest fungal 
tissue burden respectively among 
immunocompetent mice (Fig. 7). The peri-
toneal effluent burdens of C. glabrata, C. 
parapsilosis and C. guilliermondii were similar 
statistically but much higher than those of C. 
tropicalis and C. lipolytica. None of the tested 
organisms was able to initiate infection in the 
pancreas in immunocompetent mice. 
Generally, immunosuppressed mice had 
significantly higher tissue burdens than 
immunocompetent ones (p<0.001) except for 
liver burdens in C. glabrata infected groups 
and peritoneal effluent counts in C. glabrata, 
C. parapsilosis and C. guilliermondii where no 
significant difference was recorded.  
 Liver and spleen represented the most 
affected intra-abdominal site of infection with 
no significant difference between their tissue 
burdens in immunosuppressed mice infected 
with C. glabrata, C. parapsilosis and C. lipo- 
lytica. Similarly, in immunocompetent models, 
C. glabrata, C. parapsilosis and C. lipolytica 
had statistically similar tissue burdens in the 
liver, spleen and peritoneal effluent. In case of 
C. tropicalis, spleen had the highest fungal 
burden followed by liver and peritoneal fluid 
respectively in both immunosuppressed and 
immunocompetent models. Similarly, in C. 
guilliermondii infected neutropenic mice, 
spleen was the most affected organ, while 
there was no significant difference between all 
organs among immunocompetent mice. Of 
note, the least fungal burdens were observed 
peritoneal effluent in almost all tested Candida 
species. The fungal disease progressed to the 
kidneys in both immunosuppressed and 
immunocompetent models of all Candida 
species. The Kidneys shared statistically similar 
fungal burdens with infected intra-abdominal 
organs in all Candida species and higher 
burdens than the liver in C. tropicalis and C. 
guilliermondii infected immunosuppressed 
models and the spleen in C. glabrata 
immunocompetent models. 
 Treatment was started for both 
immunosuppressed and immunocompetent 
models, using voriconazole for groups infected 
with C. parapsilosis, C. lipolytica and C. 
guilliermondii and micafungin for C. tropicalis 
and C. glabrata groups from the Vitek 2 
system results (Table 4). All Candida species 
caused relatively high mortality (20 - 60%) in 
spite of the significant increase in the mean 
survival time after receiving treatment in all 
immunosuppressed mice. No significant 
difference in the mean survival time between 
immunosuppressed mice infected with different 
Candida strains after treatment.  
 In the treated immunocompetent 
model, all the tested animals survived the 
entire duration of the experiment, however, 
the increase in survival time compared to 
untreated groups was significant only for C. 
glabrata and C. tropicalis. Also, the difference 
in the mean survival time between treated 
immunosuppressed and treated immuno- 
competent mice was significant in case of C. 
glabrata only. 
      
Table 4: Antifungal susceptibility of the tested strains using Vitek2 System 
FLU: Fluconazole; VOR: Voriconazole; CAS: Caspofungin; MIC: Micafungin; AB: Amphotericin B; AFC: flucytosine 
 FLU VOR CAS MIC AB AFC 
C. glabrata 64 8 0.25 0.06 0.5 
1 
C. parapsilosis 2 0.12 1 1 0.25 
1 
C. lipolytica 2 0.12 0.5 0.5 0.25 
1 
C. tropicalis 1 0.12 0.25 0.06 0.25 
1 








 Interestingly, despite the significant 
reduction of fungal burden among immuno- 
suppressed animals to voriconazole and 
micafungin, their fungicidal effect (i.e., organ 
sterilization) was never observed. Also, groups 
of immunosuppressed mice infected with 
different Candida species had statistically 
similar fungal burdens in all organs after 
receiving treatment. For each Candida strain, 
there was no significant difference between 
tissue burdens of different organs, except for 
C. glabrata where kidneys had the highest 
burden of all organs. In contrast, organ 
homogenates from immunocompetent mice 
showed no detectable growth after treatment 
except the kidneys, liver and spleen of C. 
glabrata infected mice. 
Discussion: 
 This model aims to study the 
pathogenicity and in vivo susceptibility of non-
albicans Candida species associated with IAC in 
human to predict the frequency of infections, 
the outcome of clinical disease and response to 
antifungal therapy. By mimicking clinical 
situations in humans as closely as possible, 
experimental non-albicans Candida infections 
were induced in both immunocompetent and 
immunosuppressed mice intraperitoneally with 
Candida strains associated with human disease 
isolated from cases of abdominal surgeries, 
liver transplantation and continuous 
ambulatory peritoneal dialysis (CAPD).  
 Our results showed persistent infection 
in the peritoneal cavity with peritonitis, 
hepatosplenomegaly and abscess formation 
upon infection with non-albicans Candida 
species, especially in immunosuppressed 
animals. Liver and spleen were the main intra-
abdominal sites of infection and pancreas was 
affected only in case of C. tropicalis-infected 
immunosuppressed mice. This result is at 
variance with a previous intra-abdominal 
model of infection (3), where abscess 
formation on intra-abdominal organs was the 
main manifestation and pancreas being the 
most predominant site of involvement in the 
case of intraperitoneal injection of C. glabrata 
along with sterile feces. Cheng et al., (3) also 
reported that neutropenic mice injected with C. 
glabrata alone did not develop abscess which 
was not the case in our model, where 
abscesses developed upon challenging mice 
with different Candida species using the same 
inoculum (5x108 CFU/ml) without feces. 
Inspite of its retroperitoneal position and the 
inconsistency reported in previous studies (3), 
the kidney was included in our study as an 
indicator to assess progression of infection 
following intraperitoneal introduction of the 
fungal pathogen. The disease progressed to 
the kidneys with similar or higher burdens of 
fungal pathogens detected in the kidneys than 
intra-abdominal organs.   
 When comparing the virulence of the 
non-albicans Candida species tested in the 
present study in terms of mortality rates, 
survival time and tissue burden at 
predetermined points after infection, it was 
shown that among both naïve and 
immunosuppressed mice, C. glabrata was the 
most virulent species followed by C. tropicalis 
which had similar survival rates and mean 
survival time but less tissue burden than C. 
glabrata. C. parapsilosis and C. guilliermondii 
shared almost similar virulence, while C. 
lipolytica was the least virulent of all. Our 
results are at variance with the study 
conducted by Arendrup et al., (21), where C. 
tropicalis was reported to be more virulent 
than C. glabrata in an experimental model that 
compared different medically important 
Candida species   
 Previous animal model studies reported 
low virulence of C. glabrata with inability to 
cause severe illness or mortalities even with 
high intravenous inoculum (21-23). Our study 
reports the ability of C. glabrata to cause acute 
infection with high mortality in both 
immunosuppressed and immunocompetent 
animals. C. tropicalis was previously reported 
to be highly virulent even in immunocompetent 
mice (21, 24). These findings agree with our 
results where 100% mortality rate in both 
immunocompetent and immunosuppressed 
mice models and high tissue burdens were 
recorded. Many studies have reported the low 
virulence of C. parapsilosis with the fungi 
failing to initiate infection even in 
immunosuppressed mice (21,24,25). However, 
de Bernardis et al., (26) reported that C. 
parapsilosis could initiate infection when high 
inoculum is administered. Similarly, C. 
guilliermondii and C. lipolytica was reported to 
be weak, low-virulent fungi pathogens causing 
no mortalities among infected animals (21, 27-
29). Interestingly, our study showed high 
virulence of C. parapsilosis and C. 
guilliermondii with mortalities in immuno- 
suppressed and immunocompetent mice which 
explained their high incidence in our last 
survey on IAC, where they represented the 
most prevalent non-albicans Candida species 
(30). Although C. lipolytica was the weakest 
pathogen in terms of mortality rates, survival 
time and tissue burdens in both 
 




immunocompetent and immunosuppressed 
mice in our study, it caused mortality in 
immunosuppressed mice only, and lower than 
those caused by other tested species.  
 An increasing concern is being 
expressed about the emergence of antifungal 
resistance with accompanying increase in the 
prevalence of non-albicans Candida species 
among critically ill patients (9). Amphotericin 
B, fluconazole and echinocandins are the most 
commonly used antifungals in treating IAC 
(14). In our study, amphotericin B and 
fluconazole were excluded from treatment 
options according to the invitro susceptibility 
results. Micafungin was used invivo to treat 
mice infected with C. tropicalis, which reduced 
the fungal burden in all organs, and prolonged 
the survival time to some degree, however, it 
was not able to significantly reduce mortality 
rates or sterilize all organs in our 
immunosuppressed model. This finding agrees 
with the results of other studies, where 
micafungin did not completely resolve 
infections with C. glabrata (19, 31) and C. 
tropicalis (32).    
 Voriconazole was used in our study to 
treat C. parapsilosis, C. lipolytica and C. 
guilliermondii, which lowered the mortality rate 
and tissue burden in the mice organs. Zhao et 
al., (33) reported that fluconazole, itraconazole 
and posaconazole should not be used to treat 
C. lipolytica, but voriconazole may be useful 
for treatment. Our results agree with a 
previous experimental murine infection by C. 
guilliermondii where voriconazole was reported 
to be experimentally effective (34). Previous 
studies also reported that C. parapsilosis 
exhibited good susceptibility to voriconazole in 
vitro (35,36). However, voriconazole failed to 
completely eradicate the infection in 
immunosuppressed mice in our study.   
 In conclusion, IAC in Egypt is 
witnessing predominance of non-albicans 
Candida with species distribution and 
pathogenicity different from those reported 
worldwide. Further studies involving larger 
number of strains, tested with different inocula 
and several antifungal agents against each 
strain should be conducted to better 
understand the pathogenesis of the disease 
and predict treatment outcomes in clinical 
practice. 
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